Skip to content

FDA Delays Decision on First Oral Pill for Sickle Cell Disease by Three Months

November 3, 2026
FDA Delays Decision on First Oral Pill for Sickle Cell Disease by Three Months

Medicine & Healthcare

By TrendScope Daily Team · November 3, 2026

Share Facebook X WhatsApp LinkedIn Copy Link

The U.S. Food and Drug Administration has pushed back by three months its decision on whether to approve the first-ever disease-modifying pill for sickle cell disease, after regulators asked Agios Pharmaceuticals for additional safety data and then classified the company’s response as a “major amendment” to the application. The agency’s new target action date for mitapivat, an oral pyruvate kinase activator already sold for two rarer blood disorders, is now February 1, 2027, up from the original November 1, 2026 deadline, Agios announced on October 30.

The delay does not signal rejection. It reflects an unresolved question the FDA has been sitting with since early October: whether mitapivat needs a Risk Evaluation and Mitigation Strategy, or REMS, for sickle cell patients the way it already does for thalassemia patients taking the same drug under the brand name Aqvesme.

A three-month “major amendment”

According to Agios, the FDA sent an information request on October 9 asking the company to clarify whether a REMS program would be required for mitapivat’s use in sickle cell disease. Agios responded on October 19 with roughly nine months of updated safety data drawn from the ongoing open-label extension periods of its Phase 2 and Phase 3 RISE UP trials. On October 28, the FDA notified the company that it was classifying that submission as a major amendment — a designation that automatically adds three months to the review clock under standard PDUFA rules.

The supplemental New Drug Application was filed under the accelerated approval pathway and had already been granted Priority Review in July 2026, which had compressed the agency’s target review window to six months instead of the standard ten.

What the RISE UP trial showed

The application rests on RISE UP, a global, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 207 patients age 16 and older with sickle cell disease. Participants were randomized 2:1 to mitapivat 100 mg twice daily or placebo over a 52-week double-blind period. The trial hit one of its two primary endpoints: 40.6% of patients on mitapivat (56 of 138) achieved a hemoglobin response of at least 1.0 g/dL, compared with 2.9% on placebo (2 of 69) — a highly statistically significant difference. Mean hemoglobin rose 0.769 g/dL on drug versus 0.026 g/dL on placebo, and markers of red blood cell breakdown, including indirect bilirubin, also improved.

The trial’s second primary endpoint — the annualized rate of sickle cell pain crises — was not met. Patients on mitapivat had a rate of 2.62 crises per year versus 3.05 on placebo, a difference that did not reach statistical significance across the full study population, though patients who did achieve the hemoglobin response threshold tended to show more benefit on pain-related measures. Transfusion use dropped meaningfully in the mitapivat arm: 23.9% of treated patients required a transfusion during the study period, versus 40.6% on placebo, a 41% relative reduction.

The liver-safety question carried over from thalassemia

The REMS question tracing back to mitapivat’s thalassemia program is central to the holdup. In the trials supporting Aqvesme, Agios’s mitapivat brand for alpha- and beta-thalassemia, 5 of 301 patients experienced liver injury reactions, two of them serious, prompting a boxed warning and a mandatory REMS for that indication. Agios says no sickle cell patient in the RISE UP extension data has shown hepatocellular injury matching that pattern or severity, and that the drug’s benefit-risk profile in sickle cell disease remains unchanged. Labeling discussions with the FDA, including whether any REMS elements will apply, are ongoing.

“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease. We are launch-ready, building on our commercial infrastructure, and we will continue to work expeditiously with the goal of bringing mitapivat to patients.”

— Brian Goff, Chief Executive Officer, Agios Pharmaceuticals

A race against a rival pill

Agios is not alone in this drug class. Novo Nordisk’s etavopivat, another oral pyruvate kinase activator, met both primary endpoints in its own Phase 3 sickle cell trial earlier in 2026, including a reported 27% reduction in pain crises compared with placebo, and Novo has said it plans to file for approval in the second half of 2026. Because etavopivat works through the same mechanism, it could face the identical REMS question the FDA is now weighing for mitapivat, making the resolution of Agios’s case something of a bellwether for the entire drug class.

What’s next

Roughly 100,000 Americans live with sickle cell disease, according to the Centers for Disease Control and Prevention, with the condition disproportionately affecting Black Americans and historically receiving far less drug-development investment than its prevalence would suggest. If approved, mitapivat would become the first oral disease-modifying therapy for the condition, administered as a twice-daily pill rather than an infusion. Agios is also running REIGNITE, a required confirmatory Phase 3 trial under the accelerated approval pathway, which dosed its first patient in July 2026 and is tracking whether mitapivat reduces transfusion burden in patients as young as 12. For now, patients, physicians, and investors are watching February 1, 2027 — the FDA’s new deadline to decide whether mitapivat’s benefits in sickle cell disease outweigh the liver-safety questions still being worked out.

Quick questions

What is mitapivat?

Mitapivat is an oral pyruvate kinase activator from Agios, already sold for two rarer blood disorders, now under review for sickle cell disease.

What is the new FDA decision date for mitapivat?

February 1, 2027, three months later than the original November 1, 2026 date.

Does the delay mean mitapivat was rejected?

No. The FDA classified Agios’s response as a major amendment while it considers whether a REMS safety programme is needed.

Related on TrendScope Daily


People managing chronic anemia or sickle cell disease often track markers like oxygen saturation at home between doctor visits. A reliable fingertip pulse oximeter can help patients log trends to discuss with their hematologist — though it is not a substitute for clinical blood testing or medical advice.

As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.

Share Facebook X WhatsApp LinkedIn Copy Link